Nistala et al., 2011 - Google Patents
Th17 cells that undergo plasticity to a Th1 phenotype in human autoimmune arthritis can be detected by the expression of CD161 within the inflamed jointNistala et al., 2011
View PDF- Document ID
- 5157986164200641305
- Author
- Nistala K
- Adams S
- Cambrook H
- Ursu S
- Olivito B
- de Jager W
- Evans J
- Cimaz R
- Bajaj-Elliott M
- Wedderburn L
- et al.
- Publication year
- Publication venue
- Clinical and Experimental Rheumatology
External Links
Snippet
OBJECTIVES: To identify genes with disease-specific expression patterns of patients diagnosed with jSpA and healthy controls using microarray-based methods. METHODOLOGY: Peripheral blood samples of 6 HLA-B27/B7, double positive “patients …
- 230000014509 gene expression 0 title abstract description 42
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160159918A1 (en) | Methods for diagnosing and treating immune disease | |
JP2018506528A (en) | Therapeutic targets and biomarkers in IBD | |
US20140037618A1 (en) | Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants | |
Khan et al. | Ankylosing Spondylitis—Axial Spondyloarthritis | |
Nistala et al. | Th17 cells that undergo plasticity to a Th1 phenotype in human autoimmune arthritis can be detected by the expression of CD161 within the inflamed joint | |
Dimitrios | The profile of Enthesitis-Related Arthritis (ERA)–a subtype of Juvenile Idiopathic Arthritis (JIA) in Northern Greece: a retrospective cohort study | |
Alexeeva et al. | Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study | |
de la Fuente-Munoz et al. | Case Report: Novel STIM1 gain-of-function mutation in a patient with TAM/STRMK and immunological involvement | |
Vitale et al. | Axial spondyloarthritis in patients with recurrent fever attacks: data from the AIDA network registry for undifferentiated autoInflammatory diseases (USAIDs) | |
Artsymovych et al. | EARLY REGISTRATION OF MYOCARDIAL DISORDERS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS USING THE 4TH GENERATION ELECTROCARDIOGRAPHY | |
Pinkas-Kramarski et al. | Studying the Immunomodulatory Effects of Small Molecule Ras-Inhibitors in Animal Models of Rheumatoid Arthritis | |
Oshlianska et al. | THE MAIN CHALLENGES IN THE TRANSITION OF PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS TO ADULT SERVICE IN UKRAINE | |
Gamble | JSLE and the NLRP3 inflammasome–a novel therapeutic target | |
Oshlianska et al. | THE RATIO OF SOME CYTOKINES LIKE A MARKER OPTIONS AND COURSE OF JUVENILE ARTHRITIS | |
Oshlianska et al. | THE USE OF OFF-LABEL BIOLOGICS IN CHILDREN WITH SYSTEMIC CONNECTIVE TISSUE DISEASES | |
ULAŞ GÜNCAN et al. | Patient Compliance and Safety of Intravenous Biological Drug Treatments in Hospital During the COVID-19 Pandemic. | |
Lee | Paediatric Inflammatory Bowel Disease: Epidemiology and Immunopathogenesis | |
Tüfekçi et al. | Rheumatology Congress: part 2 | |
Villanueva Martin | Deciphering the genetic basis of systemic sclerosis | |
De Nardo et al. | Scleroderma heart involvement: non-invasive assessment of pathophysiological mechanism and its effect on prognosis | |
Capria et al. | An impaired endothelial dependent and independent vasodilation characterizes the myo-endothelial dysfunction in ssc patients | |
Capria et al. | Adalimumab corrects long-term endothelial dysfunction in rheumatoid arthritis | |
Bechman | The'oRAcle'Study: Identifying Predictors of Adverse Outcomes in Rheumatoid Arthritis | |
Conway | Giant cell arteritis: diagnostic tools, treatment targets, and pathogenic pathways | |
McAllister et al. | GENETICS AND GENOMICS OF CHRONIC INFLAMMATORY DISORDERS, II: RHEUMATOID ARTHRITIS AND RELATED ARTHROPATHIES |